FLT3 and acute myeloid leukemia: A study by the Austrian-German Acute Myeloid Leukemia Study Group (AGAMLS) of FLT3-ITD+ AML patients who were treated with midostaurin and either relapsed or had refractory response, showed loss of FLT3-ITD mutation in nearly half of the patients.